





NAT & IGO

Joint Meeting

May 31st & June 1st 2021

PROGRAMME



DAY 1 - MONDAY, MAY 31ST

01:45 pm Welcome Speech - Carole Guillonéau, U1064 CRTI, Nantes, France

SESSION I - BIOREAGENTS

Chairmen: Paolo Dellabona & Carole Guillonéau

02:00 pm IL-2-based immunotherapies for (dis)-engaging Tregs - Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris

02:30 pm Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer - Jean-François Fonteneau, CRCINA, INSERM U1232, Labex IGO, Siric ILIAD, Nantes

03:00 pm Harnessing Innate Immunity in Cancer Therapy - Eric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML/Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France

03:30 pm Targeting Trained Immunity in Organ Transplantation - Jordi Ochando, Icahn School of Medicine at Mount Sinai, New York City, USA

04:00 pm

SHORT BREAK



SESSION II - ADVANCED CELL THERAPY
Chairmen: Dimitrios L. Wagner & Nathalie Labarrière

- 04:30 pm IL-10-producing dendritic cell biology and their applications to control unwanted immune responses - **Silvia Gregori, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy**
- 05:00 pm Overcoming barriers to efficacy for engineered T cells in solid tumors - **Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA**
- 05:30 pm Reprogramming Human Immune Cells with CRISPR - **Alexander Marson, University of California, San Francisco, USA**
- 06:00 pm Keynote speech - Human T cell differentiation epigenomic atlas and T cell exhaustion - **E. John Wherry, university of Pennsylvania, Philadelphia, USA**



DAY 2 - TUESDAY, JUNE 1ST

Selected communications (10 min each + 5 min for questions)
Chairmen: Sophie Brouard & Mikaël Roussel

- | | |
|----------|--|
| 9:30 am | Enhancing CAR T-cell therapies with precision genome engineering – Laurent Poirot, Collectis |
| 9:45 am | Immunosuppressant-resistant T cell products for improved functionality in immunosuppressed patients - Leila Amini, Berlin Institute of Health, Center for Regenerative Therapies, Berlin Center for Advanced Therapies, Charité Universitätsmedizin Berlin – CVK |
| 10:00 am | Critical Role of the Regulatory Cytokine IL-34 in Treg Function – Ignacio Anegón, CRTI, UMR 1064 INSERM, University of Nantes |
| 10:15 am | Human microbiota-induced TREGS: potential roles in homeostasis and diseases - Emmanuelle Godefroy, CRCINA, UMR1232 INSERM, University of Nantes |
| 10:30 am | The C-type Lectin CLEC-1 by suppressing dendritic cell antigen presentation represents a novel myeloid immune checkpoint target for cancer immunotherapy - Marion Drouin, CRTI, UMR 1064 INSERM, University of Nantes |
| 10:45 am | Agonist anti-ChemR23 mAb blunts tissue neutrophil accumulation and triggers chronic colitis inflammation resolution - Charlène Trilleaud, OSE Immunotherapeutics, Nantes |
| 11:00 am | Blocking PDGFR α signaling ameliorates multiple sclerosis-like neuroinflammation by inhibiting disruption of the blood brain barrier - Manuel Zeitelhofer, Karolinska Institute, MBB, Vascular Biology Unit, Stockholm, Sweden |
| 11:15 am | The myeloid lineage is required for the emergence of a regeneration permissive environment following Xenopus tail amputation - Jerome Jullien, Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK |
| 11:30 am | Impact of inflammation on the specific CD4+ T cell and antibody responses during antigen expression in the mouse liver - Anaïs Cardon, CRTI, UMR 1064 INSERM, University of Nantes |
| 11:45 am | Characterizing the BK polyomavirus-specific B-cell repertoire in kidney transplant recipients with BK reactivation - Dorian McIlroy, CRTI, UMR 1064 INSERM, University of Nantes |
| 12:00 am | Showing of our sponsors promotional films |



SESSION III - NEW HORIZONS

Chairmen: Megan Sykes & Catherine Rabu

- 01:45 pm Deep Profiling of Tissue Ecosystems by Imaging Mass Cytometry - Nicolas Damond, Bodenmiller Lab, Department of Quantitative Biomedicine, University of Zurich, Switzerland
- 02:15 pm Mesenchymal stromal cell heterogeneity: implication for their clinical application - Karin Tarte, Inserm U1236, University of Rennes, CHU Rennes, France
- 02:45 pm Reconstructing the human immune system using single cell genomics - Laura Jardine, Biosciences Institute, Newcastle University, UK
- 03:15 pm Targeting common epithelial malignancies with TCR engineered lymphocytes specific for 'public' neoantigens - Christopher Klebanoff, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA
- 03:45 pm SHORT BREAK

SESSION IV - TISSUE MICROENVIRONMENT

Chairmen : Barbara Seliger & Jérôme Martin

- 04:15 pm Immunoregulation of inflammation - Renato Monteiro, Center for Research on Inflammation - INSERM U1149 & CNRS ERL8252 / Paris Diderot Faculty of Medicine
- 04:45 pm Myeloid cells and cancer immunotherapy - Antonio Sica, Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center, Milan, Italy
- 05:15 pm TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy - Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel
- 05:45 pm Immune escape mechanisms of tumors and their impact for immunotherapies - Barbara Seliger, Institute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, Germany
- 06:15 pm Evolution of a Stromal-Immune Axis in Cancer Immunology and Immunotherapy - Shannon Turley, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA
- 06:45 pm Awarding ceremony (best oral presentation, best poster)

